Indietro

Boston Scientific Corp

Ticker: BSX ISIN: US1011371077
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap
Capitalizzazione
83,24 Mld $
P/E
23,43
Forward P/E
16,61
Profit margin
17,29%
Revenue growth QoQ
11,60%
Beta
0,62
49,01 $ -2,70%
Prezzo al 2026-08-24 · NYSE

Performance per periodo

Rendimenti cumulativi
1 Month +7,69%
6 Months -34,78%
1 Year -53,37%
5 Years +1,88% p.a.+9,74%
10 Years +7,27% p.a.+101,69%
Since inception +6,77% p.a.+413,19%
Rendimenti per anno
YTD -48,60%
2025 +6,75%
2024 +54,51%
2023 +24,94%
2022 +8,92%
2021 +18,16%

Key stats

Market cap
83,24 Mld
P/E
23,43
Beta
0,62
52-week range
54.98 - 109.50
50-day MA
65,84
200-day MA
89,28
Section 1

Business overview

Company profile data from fundamentals.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 14,66%
ROA 6,07%
Profit margin 17,29%
Operating margin 20,60%
PEG ratio 0,68
Revenue/share TTM 13,91
Revenue TTM 20,61 Mld
EBITDA 5,50 Mld
Gross profit TTM 14,21 Mld
Beta 0,62

Valuation

Trailing P/E 23,43
Forward P/E 16,61
P/B 3,22
P/S 4,04
EV/EBITDA 16,89
EV/Revenue 4,50

ESG Scores

Total ESG 29,2
Environment 1,5
Social 12,9
Governance 7,9
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 3,38
Quarterly earnings growth 100,00%
Revenue TTM 20,61 Mld
Reported quarters 119
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Split factor 2:1
Last split date 2003-11-06
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 117,02 $
Analyst rating 4.5882

Ownership & short interest

Shares outstanding 1,48 Mld
Shares float 1,48 Mld
Institutional ownership 93,65%
Insider ownership 18,80%
Short ratio 1,66
Short % of float 1,73%

Details

Instrument metadata and source update timestamps.

Symbol BSX
Name Boston Scientific Corp
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US1011371077
Country USA
Code + exchange BSX.NYSE
Fundamentals updated 2026-05-07

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.